LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Home・Akciju saraksts・AnaptysBio Inc

AnaptysBio Inc

Slēgts

SektorsVeselības aprūpe

54.79 -1.63

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

53.67

Max

55.09

Galvenie mērījumi
By Trading Economics
Ienākumi	54M 15M
Pārdošana	54M 76M
Peļņas marža	19.802
Darbinieki	136
EBITDA	57M 38M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+54.41% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 4. marts

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	511M 1.5B
Iepriekšējā atvēršanas cena	56.42
Iepriekšējā slēgšanas cena	54.79

Ziņu noskaņojums

By Acuity

25%

75%

37 / 352 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

19.25 / 21.135 Atbalsts un pretestība

AnaptysBio Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 1. marts 23:35 UTC

Galvenie ziņu notikumi

Oil Prices Jump in Asia as U.S.-Iran Conflict Stokes Supply Fears -- Energy Comment

2026. g. 1. marts 23:49 UTC

Tirgus saruna

Galvenie ziņu notikumi

Australian Gold-Mining Stocks Rally as Attack on Iran Drives Gold Higher -- Market Talk

2026. g. 1. marts 23:47 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold, Silver Rise as Middle East Conflict Spurs Safe-Haven Demand -- Market Talk

2026. g. 1. marts 23:41 UTC

Tirgus saruna

Galvenie ziņu notikumi

Lasting Oil Price Shock Could Stoke Global Inflation -- Market Talk

2026. g. 1. marts 23:39 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Equities Roundup: Market Talk

2026. g. 1. marts 23:39 UTC

Tirgus saruna

Galvenie ziņu notikumi

Nikkei May Fall Amid Concerns About Higher Energy Prices -- Market Talk

2026. g. 1. marts 23:36 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Jumps as Middle East Conflict Heightens Supply Disruption Concerns -- Market Talk

2026. g. 1. marts 23:24 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2026. g. 1. marts 23:24 UTC

Tirgus saruna

Financial Markets Trim Bets on RBA Hike in May -- Market Talk

2026. g. 1. marts 23:21 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 1. marts 23:21 UTC

Tirgus saruna

Sky Network TV's Risk/Reward Still Not Attractive -- Market Talk

2026. g. 1. marts 23:19 UTC

Galvenie ziņu notikumi

Front-Month Brent Crude Oil Futures Rose 8.5% to $79.08/bbl

2026. g. 1. marts 23:17 UTC

Galvenie ziņu notikumi

Front-Month WTI Crude Oil Futures Rose 8.4% to $72.65/bbl

2026. g. 1. marts 23:14 UTC

Galvenie ziņu notikumi

Front-Month WTI Crude Oil Futures Extend Gains in Early Trade

2026. g. 1. marts 22:55 UTC

Galvenie ziņu notikumi

Spot Gold Rises 1.9% to $5,278.61/oz Amid Middle East Conflict

2026. g. 1. marts 22:54 UTC

Galvenie ziņu notikumi

Front-Month WTI Crude Oil Futures Rise Amid Middle East Conflict

2026. g. 1. marts 22:53 UTC

Galvenie ziņu notikumi

Front-Month WTI Crude Oil Futures Rise 3.2% to $67.29/bbl

2026. g. 1. marts 22:38 UTC

Tirgus saruna

Galvenie ziņu notikumi

Attack on Iran Likely to Push Up Floor Under Gold -- Market Talk

2026. g. 1. marts 22:21 UTC

Peļņas

Berkshire's Earnings Weren't as Bad as They Looked. A Goodwill Write-Down Hit Operating Profits. -- Barrons.com

2026. g. 1. marts 22:17 UTC

Tirgus saruna

Financial Markets Trim Bets On RBA Hike In May -- Market Talk

2026. g. 1. marts 22:13 UTC

Tirgus saruna

Galvenie ziņu notikumi

OPEC+ Oil Output Boost Could Be Moot if Strait of Hormuz Unavailable -- Market Talk

2026. g. 1. marts 22:00 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Could Surge Above $100 If Flows Don't Return to Normal Quickly -- Market Talk

2026. g. 1. marts 21:40 UTC

Tirgus saruna

Galvenie ziņu notikumi

Spot Gold Up as Investors Shield Against Risk -- Market Talk

2026. g. 1. marts 21:35 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Prices Seen Rising to Low to Mid-US$80s Per Barrel -- Market Talk

2026. g. 1. marts 21:30 UTC

Tirgus saruna

Australian Dollar Weakens Most as Trader Fear Long-Term Conflict -- Market Talk

2026. g. 1. marts 21:27 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Prices Likely to Rise on Iran Conflict But to Manageable Levels -- Market Talk

2026. g. 1. marts 21:19 UTC

Tirgus saruna

Galvenie ziņu notikumi

Shipping Disruptions 'More Acute Risk' Than Oil Output From Iran Conflict -- Market Talk

2026. g. 1. marts 20:58 UTC

Tirgus saruna

Galvenie ziņu notikumi

Risk Off Stance in Markets Amid Fears of Wider Conflict -- Market Talk

2026. g. 1. marts 20:40 UTC

Tirgus saruna

Australia Dollar to Fall Sharply Against U.S. Dollar on Middle East Conflict -- Market Talk

2026. g. 1. marts 20:24 UTC

Tirgus saruna

Galvenie ziņu notikumi

Brent Crude at $100/bbl Could Slow Pace of Global Rate Cuts -- Market Talk

Salīdzinājums

Cenas izmaiņa

AnaptysBio Inc Prognoze

Cenas mērķis

By TipRanks

54.41% augšup

Prognoze 12 mēnešiem

Vidējais 85 USD 54.41%

Augstākais 140 USD

Zemākais 56 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi AnaptysBio Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam AnaptysBio Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

19.25 / 21.135Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Noskaņojums

By Acuity

37 / 352 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.